CELLULAR SURGERY Trademark

Trademark Overview


On Thursday, June 6, 2024, a trademark application was filed for CELLULAR SURGERY with the United States Patent and Trademark Office. The USPTO has given the CELLULAR SURGERY trademark a serial number of 98588752. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Wednesday, January 8, 2025. This trademark is owned by EXTHYMIC CORPORATION. The CELLULAR SURGERY trademark is filed in the Medical Instrument Products category with the following description:

Medical device for treating cancer; Medical devices for use in treating autoimmune diseases
cellular surgery

General Information


Serial Number98588752
Word MarkCELLULAR SURGERY
Filing DateThursday, June 6, 2024
Status641 - NON-FINAL ACTION - MAILED
Status DateWednesday, January 8, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesMedical device for treating cancer; Medical devices for use in treating autoimmune diseases

Classification Information


International Class010 - Surgical, medical, dental, and veterinary apparatus and instruments, artificial limbs, eyes, and teeth; orthopedic articles; suture materials.
US Class Codes026, 039, 044
Class Status Code6 - Active
Class Status DateThursday, June 6, 2024
Primary Code010
First Use Anywhere DateTuesday, August 1, 2023
First Use In Commerce DateTuesday, August 1, 2023

Trademark Owner History


Party NameEXTHYMIC CORPORATION
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSAN DIEGO, CA 92121-1168

Trademark Events


Event DateEvent Description
Thursday, June 6, 2024NEW APPLICATION ENTERED
Wednesday, August 14, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, December 17, 2024ASSIGNED TO EXAMINER
Wednesday, January 8, 2025NON-FINAL ACTION WRITTEN
Wednesday, January 8, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, January 8, 2025NON-FINAL ACTION E-MAILED